Trial · NCT01191801
Adverse events484
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 484
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Group A (Vosaroxin/Cytarabine) | 95 | 355 | |
| other | Anaemia | Blood and lymphatic system disorders | Group B (Placebo/Cytarabine) | 104 | 350 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Group A (Vosaroxin/Cytarabine) | 143 | 355 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Group B (Placebo/Cytarabine) | 97 | 350 | |
| other | Neutropenia | Blood and lymphatic system disorders | Group A (Vosaroxin/Cytarabine) | 70 | 355 | |
| other | Neutropenia | Blood and lymphatic system disorders | Group B (Placebo/Cytarabine) | 50 | 350 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Group A (Vosaroxin/Cytarabine) | 88 | 355 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Group B (Placebo/Cytarabine) | 90 | 350 | |
| other | Atrial fibrillation | Cardiac disorders | Group A (Vosaroxin/Cytarabine) | 22 | 355 | |
| other | Atrial fibrillation | Cardiac disorders | Group B (Placebo/Cytarabine) | 16 | 350 | |
| other | Tachycardia | Cardiac disorders | Group A (Vosaroxin/Cytarabine) | 32 | 355 | |
| other | Tachycardia | Cardiac disorders | Group B (Placebo/Cytarabine) | 29 | 350 | |
| other | Abdominal distension | Gastrointestinal disorders | Group A (Vosaroxin/Cytarabine) | 20 | 355 | |
| other | Abdominal distension | Gastrointestinal disorders | Group B (Placebo/Cytarabine) | 10 | 350 | |
| other | Abdominal pain | Gastrointestinal disorders | Group A (Vosaroxin/Cytarabine) | 79 | 355 | |
| other | Abdominal pain | Gastrointestinal disorders | Group B (Placebo/Cytarabine) | 46 | 350 | |
| other | Abdominal pain upper | Gastrointestinal disorders | Group A (Vosaroxin/Cytarabine) | 31 | 355 | |
| other | Abdominal pain upper | Gastrointestinal disorders | Group B (Placebo/Cytarabine) | 33 | 350 | |
| other | Constipation | Gastrointestinal disorders | Group A (Vosaroxin/Cytarabine) | 136 | 355 | |
| other | Constipation | Gastrointestinal disorders | Group B (Placebo/Cytarabine) | 141 | 350 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01191801/events